-+ 0.00%
-+ 0.00%
-+ 0.00%

'In REACH Real-world Analysis, 23% Risk Reduction In A1C-adjusted 3-Point MACE Was Observed For Ozempic Injection Compared To Dulaglutide'

Benzinga·06/20/2025 17:52:49
Listen to the news